Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yang-Kai Fu
Observed name:
Yangkai Fu
Institutions:
Capital Medical University,
Beijing Chao-Yang Hospital, Capital Medical University
Observed institutions:
Fujian Medical University,
Capital Medical University,
Beijing Chao-Yang Hospital, Capital Medical University,
Fujian Provincial Hospital
ORCID:
0000-0002-4683-6220
Observed ORCID:
0000-0002-4683-6220
OpenAlex ID:
A5048657559
Prognostic Value of Pathological Response for Patients with Unresectable Hepatocellular Carcinoma Undergoing Conversion Surgery
2024
·
Zhen-Xin Zeng
, Jia-Yi Wu
, et al.
·
Liver Cancer
·
31
PDF
Transarterial Chemoembolization Plus Lenvatinib and PD-1 Inhibitors for Hepatocellular Carcinoma with Main Trunk Portal Vein Tumor Thrombus: A Multicenter Retrospective Study
2023
·
Shu-Qun Li
, Jun-Yi Wu
, et al.
·
Journal of Hepatocellular Carcinoma
·
30
PDF
The TAE score predicts prognosis of unresectable HCC patients treated with TACE plus lenvatinib with PD-1 inhibitors
2023
·
Zhen-Xin Zeng
, Jia-Yi Wu
, et al.
·
Hepatology International
·
27
Outcomes of Salvage Surgery Versus Non-Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma After Conversion Therapy with Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Antibody: A Multicenter Retrospective Study
2024
·
Jun-Yi Wu
, Jia-Yi Wu
, et al.
·
Annals of Surgical Oncology
·
23
Surgical outcomes of hepatocellular carcinoma with extrahepatic bile duct tumor thrombus: a multicenter study
2023
·
Li-Ming Huang
, Zhen-Xin Zeng
, et al.
·
Frontiers in Oncology
·
7
Should associating liver partition and portal vein ligation for staged hepatectomy be applied to hepatitis B virus-related hepatocellular carcinoma patients with cirrhosis? A multi-center study
2022
·
Jia-Hui Lv
, Wei-Zhao Chen
, et al.
·
HPB
·
5
Efficacy and Safety of Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Inhibitors for Hepatocellular Carcinoma Patients with Extrahepatic Metastases: A Multicenter Retrospective Study
2024
·
De-Yi Liu
, Yi-Nan Li
, et al.
·
Journal of Hepatocellular Carcinoma
·
3
PDF
Impact of Duration of Adjuvant Therapy on Patients with Initially Unresectable Hepatocellular Carcinoma After Conversion Surgery: A Propensity Score Matching Study
2024
·
Zhong-Tai Lin
, Shao-Ming Wei
, et al.
·
Journal of Hepatocellular Carcinoma
·
1
PDF
Combination Therapy Consisting of Transarterial Chemoembolization, Lenvatinib, and Programmed Cell Death Protein 1 Blockade for Hepatocellular Carcinoma with Inferior Vena Cava Tumor Thrombus: A Case Series Study and Literature Review
2024
·
Yang-Kai Fu
, Yi-Nan Li
, et al.
·
Oncology Research and Treatment
·
1
PDF
Perioperative lenvatinib combined with tislelizumab plus transcatheter arterial chemoembolization in resectable hepatocellular carcinoma with high-risk of recurrence: A prospective, single-arm, phase 2 trial.
2024
·
Jia-Yi Wu
, Yang-Kai Fu
, et al.
·
Journal of Clinical Oncology
·
1
Vitamin B12 Alleviates Hepatic Ischemia–Reperfusion Injury with Restoration of Propanoate Metabolism and Mitochondrial Function
2026
·
Simeng Lei
, Zhenyu Zheng
, et al.
·
Journal of Inflammation Research
PDF
Long-term surgical outcomes of bile duct tumor thrombus versus portal vein tumor thrombus for hepatocellular carcinoma: a propensity score matching analysis
2024
·
Yi-Nan Li
, Shao-Ming Wei
, et al.
·
Frontiers in Oncology
PDF
ASO Author Reflections: Impact of Salvage Surgery in Unresectable Hepatocellular Carcinoma After Conversion Therapy: Should it be Recommended?
2024
·
Jun-Yi Wu
, Jia-Yi Wu
, et al.
·
Annals of Surgical Oncology
Show more works
View as search
Works count:
13
Citation count:
129
H-index:
5
I10-index:
4
Year
Topic
Type